CMMB Chemomab Therapeutics


Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

Special General Meeting of Shareholders

On October 25, 2021, Chemomab Therapeutics Ltd. (the “Company”) held a special general meeting of its shareholders (the “Special Meeting”). There were 97,437,080 ordinary shares of the Company represented by proxy at the Special Meeting, constituting approximately 42.74% of the outstanding ordinary shares on October 1, 2021, the record date for the Special Meeting.

The sole matter voted upon at the Special Meeting and the final results of such voting is set forth below:

Proposal: To approve the terms of employment of Dr. Dale Pfost, who was engaged as the Chief Executive Officer of the Company on September 1, 2021.


Additionally, out of the total votes cast, there were 97,133,900 votes cast by shareholders who indicated that they are not controlling shareholders and do not have a personal interest in the proposal and 303,180 votes cast by shareholders who indicated that they are controlling shareholders and have a personal interest in the proposal. Accordingly, the requisite majority required under the Israeli Companies Law, 5759-1999 was satisfied for this proposal.

The terms of compensation of Dr. Dale Pfost, which were approved under this proposal, is further described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on September 19, 2021.

Exhibit Index

Exhibit 104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

- 2 -